Literature DB >> 12095833

Loss of fragile histidine triad (FHIT) expression and microsatellite instability in periocular sebaceous gland carcinoma in patients with Muir-Torre syndrome.

Leonard M Holbach1, Alexander von Moller, Carsten Decker, Anselm G M Jünemann, Carmen Rummelt-Hofmann, Wolfgang G Ballhausen.   

Abstract

PURPOSE: To report fragile histidine triad expression and microsatellite instability in periocular sebaceous gland carcinoma.
DESIGN: Interventional case series.
METHODS: Biopsy specimens of periocular sebaceous gland carcinoma obtained from six patients (mean age, 60 +/- 17 years; range, 38 to 83 years, 5 male, 1 female) with Muir-Torre syndrome and histopathologically proven sebaceous gland carcinoma were studied immunohistochemically for the presence of fragile histidine triad protein. Polymerase chain reaction-based analysis of the markers BAT25, BAT26, D2S123, D5S346, and D17S250 was performed for microsatellite instability in tumorous and matching normal tissues.
RESULTS: Fragile histidine triad protein was detectable in the sebaceous gland carcinoma from one patient with microsatellite instability. It was not detectable in sebaceous gland carcinoma specimens from five patients without any evidence of microsatellite instability.
CONCLUSION: Inactivation of fragile histidine triad tumor suppressor gene or inactivation of the mismatch-repair system resulting in microsatellite instability may contribute to the development of periocular sebaceous gland carcinoma in Muir-Torre syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095833     DOI: 10.1016/s0002-9394(02)01434-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  11 in total

1.  [Differential eyelid tumor diagnosis. I].

Authors:  L Holbach; C Cursiefen; A Jünemann; A Viestenz; A Nasr
Journal:  Ophthalmologe       Date:  2002-05       Impact factor: 1.059

2.  [Differential diagnosis and treatment options for conjunctival tumors].

Authors:  L M Holbach; P Pogorelov; F E Kruse
Journal:  Ophthalmologe       Date:  2007-06       Impact factor: 1.059

Review 3.  Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications.

Authors:  Sara C Shalin; Stephen Lyle; Eduardo Calonje; Alexander J F Lazar
Journal:  Histopathology       Date:  2010-01       Impact factor: 5.087

4.  [Recurrent eyelid tumors with different dignities].

Authors:  U Löw; C S L Müller; E Zemova; F A Flockerzi; B Seitz
Journal:  Ophthalmologe       Date:  2019-11       Impact factor: 1.059

Review 5.  [Therapy options for malignant eyelid tumors].

Authors:  M Weiling; A Bergua; F E Kruse; L Holbach
Journal:  Ophthalmologe       Date:  2016-12       Impact factor: 1.059

6.  Loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma.

Authors:  Yu-Ping Xiao; Dong-Ying Wu; Lei Xu; Yan Xin
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

7.  Frequency and clinical features of visceral malignancy in a consecutive case series of patients with periocular sebaceous gland carcinoma.

Authors:  R Max Conway; Alexander von Moller; Wolfgang Ballhausen; Anselm Jünemann; Leonard M Holbach
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-06-29       Impact factor: 3.117

Review 8.  The FHIT gene product: tumor suppressor and genome "caretaker".

Authors:  Catherine E Waters; Joshua C Saldivar; Seyed Ali Hosseini; Kay Huebner
Journal:  Cell Mol Life Sci       Date:  2014-10-05       Impact factor: 9.261

9.  Exome-wide single-base substitutions in tissues and derived cell lines of the constitutive Fhit knockout mouse.

Authors:  Carolyn A Paisie; Morgan S Schrock; Jenna R Karras; Jie Zhang; Satoshi Miuma; Iman M Ouda; Catherine E Waters; Joshua C Saldivar; Teresa Druck; Kay Huebner
Journal:  Cancer Sci       Date:  2016-02-23       Impact factor: 6.716

10.  Cancer and the FRA3B/FHIT fragile locus: it's a HIT.

Authors:  K Huebner; C M Croce
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.